Gabapentin reduces behavioral signs of stimulus-evoked allodynia and hyperalgesia in preclinical studies of traumatic nerve injury, but its effects on more clinically relevant measures of stimulus-independent pain are unclear. To address this gap, we determined whether gabapentin would relieve affective pain after spared nerve injury (SNI). Twelve days after sham or SNI surgery, we administered gabapentin over three consecutive conditioning days and then evaluated conditioned place preference. Gabapentin produced conditioned place preference and reversed mechanical hypersensitivity in SNI but not sham rats at a dose (100 mg/kg) that did not change open-field activity. These results show for the first time that gabapentin provides relief from affective pain without producing sedation, and add to the limited clinical literature suggesting that its use can be extended to treat pain arising from traumatic nerve injury. NeuroReport 26:522-527
Introduction
Preclinical research targeting discovery of novel treatments for neuropathic pain primarily rely on mechanical or thermal stimulus-evoked behavioral outcomes. However, this approach fails to mimic the affective and spontaneous aspects of chronic pain that are most relevant to pharmacotherapy in humans, as indicated by the high failure rate of analgesic drug candidates in clinical trials. The use of conditioned place preference (CPP) to assess nonevoked pain, originally described two decades ago [1] , has re-emerged as a leading measure of affective neuropathic pain [2] and has the potential to address the disconnect between preclinical and clinical efficacy [3] . The use of CPP to measure preclinical pain relief is advantageous because the test is performed in the absence of an exogenous stimulus [4] , incorporates the motivation to seek reward [5] , and evaluates the affective [2] pain-relieving effects of analgesic drug administration [3] .
Gabapentin (Neurontin) is a primary treatment for neuropathic pain [6] in patients with trigeminal neuralgia [7] , postherpetic neuralgia [8] , painful chemoneuropathy [9] , and painful diabetic neuropathy [10, 11] . Reverse translation studies in rodents have indicated that gabapentin attenuates affective pain produced by cisplatin [12] or streptozotocin [13] , as well as the evoked hypersensitivity associated with traumatic nerve injury [14] . However, no study has evaluated whether gabapentin reduces affective pain after traumatic nerve injury. To address this question, we performed gabapentin CPP in rats with spared nerve injury (SNI), a widely used preclinical model of traumatic nerve injury [15] .
Materials and methods

Animals
Male Sprague-Dawley rats (Charles River Laboratories, Wilmington, Massachusetts, USA) weighing 200-250 g at the time of surgery and 300-350 g at the time of behavioral procedures were housed two per cage on a 12-h light/dark cycle (7 a.m. lights on/7 p.m. lights off) in a temperature (68-72°F) and humidity controlled room with food and water provided ad libitum. All efforts were made to minimize animal suffering, to reduce the number of animals used, and to utilize alternatives to in-vivo techniques, in accordance with the International Association for the Study of Pain and the National Institutes of Health Office of Laboratory Animal Welfare Guide for the Care and Use of Laboratory Animals. All behavioral procedures were carried out between 8 a.m. and 6 p.m. and were approved by the Institutional Animal Care and Use Committee at the University of Kentucky. Behavioral measurements were performed by an observer blinded to experimental treatments.
Spared nerve injury surgery
Sham and SNI surgeries were performed as described previously [15] . To generate surgical sham control subjects, all steps were performed except ligation and transection of the common peroneal and tibial nerves. The day of sham or SNI surgery is referred to as day 0.
Measurement of pain-like behavior and open-field activity
Animals were acclimated in individual Plexiglas boxes (4 × 8 × 4 inches) on top of a raised stainless steel mesh grid for 1 h. Mechanical hypersensitivity was assessed with von Frey filaments (Stoelting Inc., Wood Dale, Illinois, USA) using a modified up-down method [16, 17] as described previously [18] . The calculated 50% withdraw threshold is reported. A photobeam activity system (16 × 16 array; San Diego Instruments, San Diego, California, USA) was used to measure exploratory locomotion in a clear, square box surrounded by the photobeam array. Saline or gabapentin (100 mg/kg) was administered intraperitoneally before placing the rat into the open-field chamber. The total number of photobeam breaks was automatically quantified by the photobeam activity system software for 30 min in 5 min bins in the absence of any observer.
Conditioned place preference
The use of CPP as a tool to measure the ongoing aversiveness (i.e. affective pain) after injury or the preference for rewards has been well established [1, 2, 5, 19] . Eight rat CPP boxes (Med Associates, St Albans, Vermont, USA) were used to assess chamber preference before and after the drug conditioning phase. The experimental timeline and details of the CPP apparatus are illustrated in Fig. 1 . Rats were able to discriminate between the drug-paired and vehicle-paired chambers using visual (wall color), tactile (flooring), and olfactory (Lipsmackers Chapstick; Bonne Bell, Westlake, Ohio, USA) cues. Preliminary experiments indicated no preference for vanilla (white chamber) or kiwi (black chamber) chapstick olfactory cues in sham or SNI rats. To reduce the time spent in the gray chamber, lighting in the white and black chambers was adjusted to 25% of that in the gray chamber. Manual guillotine doors were used to isolate the white and black pairing chambers from the gray chamber during conditioning. Each individual CPP box was fully contained in a sound-attenuating and light-attenuating enclosure. Time of testing, animal handling method, and cleaning of the CPP boxes were held constant.
Preconditioning
The CPP procedure spanned six consecutive days. On Day 1, the subjects were acclimated to the CPP boxes for 30 min, with open access to each of the three chambers. On Day 2 (preconditioning), the animals were placed in the gray middle chamber, and then the time spent in the white or black pairing chamber was determined for 15 min. Animals that spent less than 20% or more than 80% of their time in the black and/or white chamber (i.e. showing an apparatus bias or initial, unconditioned preference) during preconditioning were removed from the experiment [2] . On the basis of these criteria, 10 animals were removed from von Frey and CPP analyses.
Conditioning
On Days 3, 4, and 5 (conditioning), we used a biased assignment approach to drug pairing: saline was paired with the preferred chamber in the morning, and gabapentin was paired with the nonpreferred chamber in the afternoon. Our biased approach was chosen for five reasons: (i) it increases assay sensitivity; (ii) it allows for a within subject design and statistical analysis [4, 20] ; (iii) of all CPP studies in 2001, 30% used a biased approach and 42% analyzed results using a difference score (postconditioning minus preconditioning) [20] ; (iv) a biased approach was very recently used to assess gabapentin CPP in the streptozotocin model of painful diabetic neuropathy [13] ; (v) Cunningham et al. [20] demonstrated that if the CPP apparatus is not biased (time spent in the white chamber = time spend in the black chamber when averaged across all subjects, as in the current study), then the use of either a biased or unbiased chamberassignment approach does not affect the ability to produce CPP.
Conditioning consisted of the following sequential steps: intraperitoneal injection, return of the animal to its home cage for 5 min, and placement of the animal within the white or black chamber for 30 min (injections were never paired with the gray, middle chamber). We used a 30 min conditioning time on the basis of reports that gabapentin maximally reduced mechanical hypersensitivity at 30-60 min after injection [12, 13] . We chose 3 days of gabapentin conditioning because 1 day was not sufficient to produce CPP in a mouse model of chemoneuropathy [12] .
Postconditioning and analysis
On day 6 (postconditioning), the animals were placed in the gray chamber, and we evaluated the time spent in either the white or black chamber. The difference score for each subject was calculated, by subtracting the time spent in the saline-paired or gabapentin-paired chamber before pairing (during preconditioning) from the time spent in each chamber after pairing (postconditioning), and then averaged within each group.
Experimental design
Evoked mechanical sensitivity was measured before sham or SNI surgery (day 0), 9 days after surgery (pre-CPP), and after completion of the CPP procedure on day 15 (post-CPP). The CPP assay was performed on days 10-15. Following post-CPP measurement of von Frey withdraw thresholds to confirm the sustained presence of mechanical hypersensitivity, saline or gabapentin (100 mg/kg) was injected intraperitoneally and von Frey thresholds were recorded 15, 30, and 60 min later. A 24 h time point was taken to determine whether the antihypersensitivity effects of gabapentin endured from one conditioning day to the next. Open-field activity after intraperitoneal saline or gabapentin administration was measured at the conclusion of von Frey and CPP experiments on day 17.
Drugs
Gabapentin (Spectrum Chemical, Gardena, California, USA) was dissolved in 0.9% saline immediately before injections and administered intraperitoneally at a volume of 0.5-1.0 ml (final dose = 100 mg/kg body weight).
Statistical analysis
A paired t-test was used to compare the effects of sham and SNI surgery on mechanical sensitivity before CPP, preconditioning versus postconditioning time spent in the CPP chambers, and CPP difference scores. The effect of gabapentin on behavior in the von Frey assay was compared for significant differences over time using repeated measures two-way analysis of variance followed by Holm-Sidak multiple comparison correction. An αvalue of 0.05 was used to determine statistical significance. All data were analyzed and graphed using Prism 6.0 (GraphPad, La Jolla, California, USA) and are presented as mean SEM.
Results
Spared nerve injury produces evoked mechanical hypersensitivity SNI evokes mechanical hypersensitivity that begins a few days after surgery and lasts for at least 6 months [15] . To compare evoked mechanical hypersensitivity and affective pain, we performed von Frey testing before surgery (baseline), before CPP (pre), after CPP (post), and for 60 min after intraperitoneal gabapentin administration in sham and SNI rats. CPP conditioning was performed at days 12-14 during established mechanical hypersensitivity. As illustrated in Fig. 2a , SNI produced hypersensitivity to von Frey mechanical stimulation at the pre-CPP time point (P < 0.0001). There was no change in mechanical thresholds in sham animals (P > 0.05).
Gabapentin reverses spared nerve injury-induced evoked mechanical hypersensitivity
After CPP testing, we assessed inhibition of SNI-induced mechanical hypersensitivity by measuring von Frey withdraw thresholds after systemic administration of gabapentin at the same dose used during CPP conditioning (100 mg/kg). Figure 2b illustrates that gabapentin significantly attenuated evoked mechanical hypersensitivity in rats with SNI at 30 min (P < 0.05) and 60 min (P < 0.05) after interperitoneal injection [drug × time; F(3,36) = 17.5, P < 0.0001]. Mechanical withdraw thresholds were slightly, but insignificantly, increased at 15 min. Sham animals did not exhibit evoked mechanical hypersensitivity (compared with baseline, P > 0.05) and von Frey withdraw thresholds were unaltered by gabapentin [drug × time; F(3,18) = 0.015, P > 0.05]. These data indicate that there is no initial bias for the CPP apparatus and that injury did not alter preconditioning preferences.
To determine whether gabapentin alleviates affective pain after traumatic nerve injury, we assessed CPP in sham and SNI rats. Figure 3a illustrates our biased conditioning approach: preconditioning time spent in the saline-paired chamber was greater than the time spent in the gabapentin-paired chamber in both sham (P < 0.05) and SNI (P < 0.0001) rats. Biased drug pairing remained counterbalanced, where half the animals received gabapentin in the white chamber and half in the black chamber. Conditioning to gabapentin produced an increase in the time spent in the gabapentin-paired chamber in SNI (P = 0.0043) but not sham rats (P = 0.2). When compared with saline difference scores, Fig. 3b illustrates a significantly higher gabapentin difference score in SNI (P < 0.0001) but not sham (P = 0.70) rats. These results indicate that gabapentin produces CPP in SNI but not sham rats at 2 weeks after injury. A previous study has indicated that the antihyperalgesic effect of gabapentin varies over time after nerve injury [21] . Future studies could investigate the ability of gabapentin to produce CPP at later time points.
Gabapentin did not change locomotor activity in sham or spared nerve injury rats
Gabapentin produces adverse effects in humans including somnolence, dizziness, peripheral edema, infection, and ataxia [8] . To address the potential effect of gabapentin on exploratory or somatomotor activity, we assessed open-field activity. Figure 4a indicates that gabapentin did not change locomotor activity in sham [drug; F(1,6) = 0.18, P > 0.05] or SNI [drug; F(1,8) = 0.005, P > 0.05] rats. Furthermore, there was no difference in activity between sham and SNI animals treated with saline [injury; F(1,8) = 0.02, P = 0.89], indicating that SNI did not change locomotor function. Additional studies are needed to evaluate alternative adverse effects of gabapentin to rule out confounding effects on mechanical thresholds or CPP.
Discussion
Here, we present the first data indicating that gabapentin relieves affective pain (i.e. produces CPP) associated with traumatic nerve injury in a preclinical model. Our current results are consistent with recent findings in other rodent models of neuropathic pain. For example, gabapentin produces CPP in mice following chronic cisplatin treatment [12] or in the streptozotocin model of type I painful diabetic neuropathy [13] . Xie et al. [14] reported that gabapentin reversed mechanical hyperalgesia associated with spinal nerve ligation, without measuring its effect on affective pain using CPP. Confirmatory CPP studies in other models such as spinal nerve ligation are needed to generalize our findings to multiple types of neuropathic pain induced by nerve injury.
The current study shares important experimental design characteristics with the studies of Park et al. [12] and Wagner et al. [13] , though in a different type of neuropathic pain (traumatic nerve injury). First, gabapentin produced CPP rapidly, within 30 min of administration. Second, gabapentin did not produce CPP in control animals, ruling out the possibility that gabapentin is intrinsically rewarding. This is in contrast to rewarding analgesic drugs such as morphine, which produce CPP in naive or uninjured subjects, thus complicating interpretation of the effects on affective pain [1, 4] . Third, gabapentin reduced both evoked and affective measures of pain. This is striking in light of recent reports indicating that other analgesic drugs such as transient receptor potential channel antagonists [22] inhibit evoked but not affective pain in preclinical models of inflammation [23] , osteoarthritis [24] , type I diabetes [19] , and SNI [19] . Fourth, a single systemic dose of 100 mg/kg was administered over three conditioning days [12, 13] . To determine whether CPP might reveal enhanced potency of gabapentin as compared with evoked measures of pain, further dose-response studies are needed.
Conclusion
We conclude that gabapentin alleviates affective pain after SNI in rodents. Further studies to determine the clinical efficacy of gabapentin for the treatment of chronic pain associated with traumatic nerve injury are warranted. Indeed, a randomized, double-blind, placebocontrolled, cross-over, multicenter clinical trial involving patients with peripheral nerve injury due to trauma or surgery reported that, compared with placebo, gabapentin provided better pain relief and increased the number of subjects with a pain reduction of at least 30% [25] . Our results highlight the importance of measuring Gabapentin attenuates affective pain associated with traumatic nerve injury. To determine affective pain relief, we performed CPP with 3 days of conditioning (saline or gabapentin; 100 mg/kg, intraperitoneally). (a) Time spent in the saline-paired chamber during preconditioning was greater than the time spent in the gabapentin-paired chamber as a result of our biased drug-pairing approach. In sham rats (n = 8), there was no change in preference during postconditioning (post) when compared with preconditioning baselines (pre). In SNI rats (n = 17), gabapentin produced an increase in the time spent in the gabapentin-paired chamber when compared with preconditioning baseline. (b) Saline and gabapentin difference scores were significantly different in SNI but not sham rats. These results taken together indicate that gabapentin induces CPP thereby relieving affective pain in rats with traumatic nerve injury. # Significantly different from "Pre-SNI Saline-paired". $ Significantly different from "Pre-SNI Gabapentin-paired". ⋆Significant difference between indicated groups. CPP, conditioned place preference; SNI, spared nerve injury. the affective component of pain in preclinical studies to better predict clinical efficacy of pain-relieving drugs.
